APPN News (update May 2 2022)
Suitable devices for point-of-care HbA1c testing
There are a number of devices which can measure HbA1c at point-of-care and are available for sale in Australia. To help GPs and practices chose suitable devices, APPN in collaboration with Pathology Technology Australia, has prepared a register which lists all of the devices approved by the Therapeutic Goods Administration (TGA).
For each of the devices the register shows how these devices perform analytically and which ones meet the performance criteria that determine which they are suitable for the purpose of the monitoring of HbA1c in patients. A full explanation of all the criteria is included in the register which can be found here.
Medicare funding for point-of-care HbA1c testing
Previously HbA1c tests only attracted Medicare rebates if performed through laboratories however, since November 1st of 2021, point-of-care glycated haemoglobin (HbA1c) tests will now be listed on Medicare Benefits Schedule under item 73812. This will allow patients access to three POC Hba1c tests in a year from a general practice for a fee of $11.80. For more information regarding HbA1c testing, please visit: APPN Test Modules - HbA1c